OOIR: Observatory of International Research

Papers

(The H4-Index of Seminars in Cancer Biology is 80. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial Board	624
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	444
Emerging applications of bacteria as antitumor agents	403
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	362
Expression of concern “Decoding T cell senescence in cancer: Is revisiting required?” [Semin. Cancer Biol. 108 (2025) 33–47]	358
Microbiome-modulated immunotherapy in oncology: Current applications and future prospects	304
Small secretory proteins of immune cells can modulate gynecological cancers	280
Advances in biology and novel treatments of SCLC	248
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	245
Deregulated transcription factors in the emerging cancer hallmarks	234
Critical DNA damaging pathways in tumorigenesis	231
Multifaceted role of chemokines in solid tumors: From biology to therapy	224
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	222
The impact of obesity and lipids on cancer: Insights into mechanisms and potential interventions	220
The emerging role of metabolic interventions in uveal melanoma	213
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	206
The IL-1 family in tumorigenesis and antitumor immunity	200
Anticancer properties of chimeric HDAC and kinase inhibitors	182
Editorial Board	181
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	180
Origins and molecular effects of hypoxia in cancer	179
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	177
Immune cellular components and signaling pathways in the tumor microenvironment	164
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	160
Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies	156

Innovative trial design in precision oncology	154
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	152
Gut microbes in gastrointestinal cancers	152
Expression of concern: “Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer” [Semin. Cancer Biol. 106–107 (2024) 43–57]	151
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	148
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	147
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	145
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	143
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	142
Genome chaos: Creating new genomic information essential for cancer macroevolution	139
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	139
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	133
Editorial Board	125
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	124
Lipid metabolism in cancer is regulated by the integrated natural product–miRNA–target axis	123
Integrating biomarkers, experimental models, genomics, and novel therapeutics for pancreatic cancer precision medicine	123
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	122
How far have we explored fungi to fight cancer?	122
Expression of concern “Immunosenescence in digestive system cancers: Mechanisms, research advances, and therapeutic strategies” [Semin. Cancer Biol. 106–107 (2024) 234–250]	121
Editorial Board	120
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	119
Reprogramming of glycolysis by chemical carcinogens during tumor development	117
The role of deiodinases on metabolic alteration in cancer	114
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	114
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	113
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	111
Atrial fibrillation in cancer patients: Epidemiology, identification and management	107
Anticancer natural products targeting immune checkpoint protein network	105
Systemic lipid metabolic alterations and the tumor microenvironment: A hidden driver of immune dysfunction	104
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	101
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	100
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	100
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	97
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	95
Editorial Board	94
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	94
Editorial Board	94
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	90
Editorial Board	89
Clinical utility of whole-genome sequencing in precision oncology	89
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	88
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	87
Mitochondria in sarcoma and carcinoma: Achilles’ heel or Hercules’ strength?	87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	87
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	87
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	87
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	86
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	85
Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	85
Microorganisms in cancer tertiary lymphoid structure formation	84

The foundational framework of tumors: Gametogenesis, p53, and cancer	84
The microbiome-immune cell interaction network: Advancing tumor immunotherapy	83
Analytical demands to use whole-genome sequencing in precision oncology	83
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	83
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	80
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	80
Microbiota and lung cancer	80
Metabolic reprogramming of tumor microenviroment by engineered bacteria	80